Clinical Update on C. diff Candidate RBX2660
Time: 11:00 am
day: Conference Day One, Track One, AM
Details:
- Discussing the pivotal Phase 3 trial results of RBX2660, demonstrating its superior efficacy in reducing recurrence of Clostridioides Difficile Infection (CDI)
- Explore the significance of FDA approval and breakthrough therapy designation for RBX2660, and its impact on accelerating the development and availability of this microbiome-based therapeutic
- Future Directions and Applications: Examine the potential expansion of RBX2660’s use in other high-risk patient populations and the ongoing efforts to address unmet medical needs in gastrointestinal health
